Global Pet Cancer Therapeutics Market, By Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Combination Therapy, and Others), Medicine Type (Chemotherapy Drugs and Vaccines), Route of Administration (Parenteral, Oral, and Others), Cancer Type (Melanoma, Mast Cell Cancer, Lymphoma, Mammary and Squamous Cell Cancer, and Others), Species Type (Cat, Dog, and Others), End User (Veterinary Hospitals and Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) – Industry Trends and Forecast to 2031.
Pet Cancer Therapeutics Market Analysis and Size
The pet cancer therapeutics market is advancing rapidly with the latest methods and technologies driving growth. Innovations such as targeted therapies and immunotherapy are transforming treatment approaches. Rising pet healthcare expenditures and increasing pet longevity contribute to market expansion. Companies are focusing on precision medicine and personalized treatments, enhancing efficacy and outcomes in managing cancer in pets.
The global pet cancer therapeutics market size was valued at USD 283.86 million in 2023 and is projected to reach USD 569.77 million by 2031, with a CAGR of 9.10% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Combination Therapy, and Others), Medicine Type (Chemotherapy Drugs and Vaccines), Route of Administration (Parenteral, Oral, and Others), Cancer Type (Melanoma, Mast Cell Cancer, Lymphoma, Mammary and Squamous Cell Cancer, and Others), Species Type (Cat, Dog, and Others), End User (Veterinary Hospitals and Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
AB Science (France), Elanco (U.S.), Candel Therapeutics (Canada), NIPPON ZENYAKU KOGYO CO., LTD. (Japan), Rhizen Pharmaceuticals AG (Switzerland), Virbac Corporation (France), Pfizer Inc. (U.S.), VetDC (U.S.), Boehringer Ingelheim International GmbH (Germany), Karyopharm (U.S.), VETCO (U.S.), ELIAS Animal Health (U.S.), Vivesto AB (Sweden), Torigen Pharmaceuticals Inc. (U.S.), and Zoetis Services LLC (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Pet cancer therapeutics refer to treatments and medications designed to diagnose, manage, and potentially cure cancer in animals. These therapies include chemotherapy, surgery, radiation, and targeted therapies tailored to specific types of cancer in pets. The goal is to improve quality of life, extend survival, and minimize pain and discomfort associated with cancer in dogs, cats, and other companion animals.
Pet Cancer Therapeutics Market Dynamics
Drivers
- Increasing Pet Ownership
Increasing pet ownership globally has led to heightened awareness and increased spending on pet healthcare, significantly boosting demand for advanced therapies in the pet cancer therapeutics market. For instance, as more households treat pets as family members, there's a greater willingness to invest in treatments such as cancer therapies, driving market growth. This trend is supported by a growing number of veterinary clinics offering specialized oncology services tailored to meet the needs of pet owners seeking advanced healthcare options.
- Advancements in Veterinary Medicine
Advancements in veterinary medicine, particularly in oncology, are driving growth in the pet cancer therapeutics market. For instance, new treatment modalities such as targeted therapies and immunotherapies offer more effective and less invasive options for treating cancer in pets. Additionally, advanced diagnostic technologies such as molecular imaging and genetic testing enable earlier detection and personalized pet cancer treatment approaches, improving outcomes and fostering higher demand for specialized veterinary oncology services and products.
Opportunities
- Regulatory Support and Guidelines
Clearer regulatory frameworks and guidelines are pivotal in driving the pet cancer therapeutics market by ensuring safer and more effective treatments. For instance, the FDA's Center for Veterinary Medicine (CVM) provides guidance on drug approval processes, ensuring products meet safety and efficacy standards. Such frameworks encourage investment in research and development, fostering innovation in treatments tailored to pets' specific cancer types, ultimately expanding treatment options and improving outcomes for companion animals.
- Improved Diagnostic Capabilities
Improved diagnostic capabilities in veterinary oncology have significantly enhanced early detection and treatment planning for pet cancers. Advanced imaging techniques such as CT scans and MRI, alongside genetic testing for biomarker identification, allow veterinarians to diagnose cancers earlier and tailor treatments more effectively. For instance, the use of next-generation sequencing helps identify specific mutations in tumors, guiding targeted therapies. This capability not only improves outcomes but also drives growth in the pet cancer therapeutics market by promoting timely and personalized treatment strategies.
Restraints/Challenges
- High Cost of Treatment
The high cost of cancer treatment for pets acts as a significant barrier, restricting access for many owners and thereby hindering market growth. The expense involved often deters potential customers from pursuing such treatments, impacting market expansion negatively. This financial constraint limits the market's potential reach and adoption among pet owners, creating a substantial hurdle for companies operating in the pet cancer therapeutics sector.
- Complexity of Treatment
Administering and monitoring cancer treatments in pets poses significant challenges due to their diverse physiology and behavioral variations. This complexity hinders market growth by complicating treatment efficacy and consistency. Veterinarians face difficulties in standardizing care across different animal species and breeds, impacting treatment outcomes. These inherent differences contribute to the overall complexity and unpredictability of managing cancer therapies in pets, creating barriers to market expansion.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In July 2022, Fort Wayne Animal Care and Control received a USD 35,000 grant from Petco Love to bolster their efforts in saving animal lives in Fort Wayne. This funding aims to enhance their capacity for animal welfare initiatives, including adoption programs and veterinary care
- In June 2022, Petco Love allocated USD 75,000 grant to Cornell University College of Veterinary Medicine. This long-standing partnership supports subsidized cancer treatments for dogs and cats, advancing veterinary oncology research and care
- In June 2022, Boehringer Ingelheim and CarthroniX embarked on a collaboration to innovate canine oncology. They aim to pioneer novel small molecule therapies for aging-related and degenerative diseases in dogs, potentially expanding Boehringer Ingelheim's Animal Health portfolio
Pet Cancer Therapeutics Market Scope
The market is segmented on the basis of therapy, medicine type, route of administration, cancer type, species type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Targeted Therapy
- Combination Therapy
- Others
Medicine Type
Route of Administration
- Parenteral
- Oral
- Others
Cancer Type
- Melanoma
- Mast Cell Cancer
- Lymphoma
- Mammary and Squamous Cell Cancer
- Others
Species Type
- Cat
- Dog
- Others
End User
- Veterinary Hospitals and Clinical Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Pet Cancer Therapeutics Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, therapy, medicine type, route of administration, cancer type, species type and end user as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the pet cancer therapeutics market due to rising prevalence, robust healthcare infrastructure, and significant research investments. These factors contribute to its leading position in advancing treatments for pets diagnosed with cancer.
Asia-Pacific is expected to expand at a significant growth in the pet cancer therapeutics market due to increasing incidence, awareness, government initiatives, and disposable incomes in the region, fostering market expansion over the forecast period.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Pet Cancer Therapeutics Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- AB Science (France)
- Elanco (U.S.)
- Candel Therapeutics (Canada)
- NIPPON ZENYAKU KOGYO CO., LTD. (Japan)
- Rhizen Pharmaceuticals AG (Switzerland)
- Virbac Corporation (France)
- Pfizer Inc. (U.S.)
- VetDC (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Karyopharm (U.S.)
- VETCO (U.S.)
- ELIAS Animal Health (U.S.)
- Vivesto AB (Sweden)
- Torigen Pharmaceuticals Inc. (U.S.)
- Zoetis Services LLC (U.S.)
SKU-